• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Optimizing the dose and schedule of immune checkpoint inhibitors in cancer to allow global access.

作者信息

Hirsch Ian, Goldstein Daniel A, Tannock Ian F, Butler Marcus O, Gilbert Duncan C

机构信息

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

出版信息

Nat Med. 2022 Nov;28(11):2236-2237. doi: 10.1038/s41591-022-02029-1.

DOI:10.1038/s41591-022-02029-1
PMID:36202999
Abstract
摘要

相似文献

1
Optimizing the dose and schedule of immune checkpoint inhibitors in cancer to allow global access.优化癌症免疫检查点抑制剂的剂量和给药方案以实现全球可及。
Nat Med. 2022 Nov;28(11):2236-2237. doi: 10.1038/s41591-022-02029-1.
2
Immune checkpoint inhibitors in cancer immunotherapy.癌症免疫治疗中的免疫检查点抑制剂
CMAJ. 2020 Jun 15;192(24):E651. doi: 10.1503/cmaj.191231.
3
Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy.免疫检查点抑制剂与癌症治疗中抗生素相互作用的分析。
Front Med. 2022 Jun;16(3):307-321. doi: 10.1007/s11684-022-0927-0. Epub 2022 Jun 1.
4
Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors.基于纳米颗粒的免疫原性细胞死亡诱导剂和免疫检查点抑制剂的联合癌症免疫疗法。
Int J Nanomedicine. 2021 Feb 22;16:1435-1456. doi: 10.2147/IJN.S285999. eCollection 2021.
5
Cancer immunotherapy with immune checkpoint inhibitors and infections: A particular focus on mycobacterial infections.癌症免疫疗法中的免疫检查点抑制剂与感染：特别关注分枝杆菌感染。
Respir Investig. 2024 May;62(3):339-347. doi: 10.1016/j.resinv.2024.02.002. Epub 2024 Feb 27.
6
A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics.癌症中新的生物学三角：肠道微生物群、免疫检查点抑制剂和抗生素。
Clin Transl Oncol. 2021 Dec;23(12):2415-2430. doi: 10.1007/s12094-021-02659-w. Epub 2021 Jun 14.
7
["Immune checkpoint inhibitors in oncology"].["肿瘤学中的免疫检查点抑制剂"]
Rev Prat. 2021 Apr;71(4):374-379.
8
Resistance to immune checkpoint blockade: Mechanisms, counter-acting approaches, and future directions.免疫检查点阻断的耐药性：机制、对抗方法和未来方向。
Semin Cancer Biol. 2022 Nov;86(Pt 3):532-541. doi: 10.1016/j.semcancer.2022.02.019. Epub 2022 Mar 9.
9
Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy.调节肠道菌群以克服癌症免疫治疗中免疫检查点阻断的耐药性。
Curr Opin Pharmacol. 2020 Oct;54:1-10. doi: 10.1016/j.coph.2020.06.004. Epub 2020 Jun 30.
10
Dawn era for revisited cancer therapy by innate immune system and immune checkpoint inhibitors.固有免疫系统和免疫检查点抑制剂重新审视癌症治疗的黎明时代。
Biochim Biophys Acta Mol Basis Dis. 2024 Mar;1870(3):167019. doi: 10.1016/j.bbadis.2024.167019. Epub 2024 Jan 9.

引用本文的文献

1
Advancing drug development with "Fit-for-Purpose" modeling informed approaches.采用“适用目的”建模指导方法推进药物研发。
J Pharmacokinet Pharmacodyn. 2025 Sep 15;52(5):52. doi: 10.1007/s10928-025-09995-2.
2
Eco Friendly and Budget Smart: An Economic and Environmental Evaluation of Alternative PD-1 and PD-L1 Inhibitor Dosing Regimens.生态友好且预算明智：替代PD-1和PD-L1抑制剂给药方案的经济与环境评估
Pharmacoeconomics. 2025 Sep 10. doi: 10.1007/s40273-025-01535-7.
3
Thermosensitive Hydrogel Sustaining the Release of Lymph-Draining Oligonucleotide Adjuvant Polyplex Micelles Improves Systemic Cancer Immunotherapy.

本文引用的文献

1
Immune-checkpoint inhibitors: long-term implications of toxicity.免疫检查点抑制剂：毒性的长期影响。
Nat Rev Clin Oncol. 2022 Apr;19(4):254-267. doi: 10.1038/s41571-022-00600-w. Epub 2022 Jan 26.
2
Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).基于早期、中期影像学评估的晚期黑色素瘤患者纳武利尤单抗+伊匹单抗免疫治疗的适应性剂量调整（ADAPT-IT 研究）。
J Clin Oncol. 2022 Apr 1;40(10):1059-1067. doi: 10.1200/JCO.21.01570. Epub 2021 Dec 20.
3
A revolving research fund to study efficient use of expensive drugs: big wheels keep on turning.
维持淋巴引流寡核苷酸佐剂多聚体胶束释放的热敏水凝胶改善全身性癌症免疫治疗。
ACS Nano. 2025 Jun 17;19(23):21775-21791. doi: 10.1021/acsnano.5c05517. Epub 2025 Jun 3.
4
Sample Size Calculation in Dose Optimization Trials Using the Margin of Practical Non-Inferiority.使用实际非劣效性界值的剂量优化试验中的样本量计算
Stat Med. 2025 May;44(10-12):e70118. doi: 10.1002/sim.70118.
5
PD-L1 imaging with [Tc]NM-01 SPECT/CT is associated with metabolic response to pembrolizumab with/without chemotherapy in advanced lung cancer.采用[锝]NM-01单光子发射计算机断层扫描/计算机断层扫描（SPECT/CT）进行程序性死亡受体配体1（PD-L1）成像与晚期肺癌患者接受帕博利珠单抗联合或不联合化疗后的代谢反应相关。
Br J Cancer. 2025 Jun;132(10):913-921. doi: 10.1038/s41416-025-02991-w. Epub 2025 Apr 5.
6
Enhancing immunotherapy with tumour-responsive nanomaterials.用肿瘤响应性纳米材料增强免疫疗法。
Nat Rev Clin Oncol. 2025 Apr;22(4):262-282. doi: 10.1038/s41571-025-01000-6. Epub 2025 Mar 6.
7
Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study.帕博利珠单抗混合给药方案在晚期非小细胞肺癌中不劣于固定剂量给药：一项真实世界、回顾性双中心队列研究。
J Immunother Cancer. 2025 Feb 6;13(2):e010065. doi: 10.1136/jitc-2024-010065.
8
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors.接受免疫检查点抑制剂治疗的错配修复缺陷或微卫星高度不稳定转移性结直肠癌患者的早期治疗中断
J Immunother Cancer. 2025 Jan 4;13(1):e010424. doi: 10.1136/jitc-2024-010424.
9
Association between tumor location and toxicity outcomes after stereotactic radiosurgery for brain metastases.脑转移瘤立体定向放射治疗后肿瘤位置与毒性结果之间的关联。
J Neurooncol. 2025 Jan;171(2):473-483. doi: 10.1007/s11060-024-04866-1. Epub 2024 Nov 15.
10
Optimal Duration of Consolidation Durvalumab Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer: A Multi-institutional Retrospective Study.III期非小细胞肺癌放化疗后巩固性度伐利尤单抗的最佳疗程：一项多机构回顾性研究
Target Oncol. 2025 Jan;20(1):161-169. doi: 10.1007/s11523-024-01105-5. Epub 2024 Nov 7.
一项用于研究昂贵药物高效使用的循环研究基金：大机构持续运转。
Ann Oncol. 2021 Oct;32(10):1212-1215. doi: 10.1016/j.annonc.2021.08.1747. Epub 2021 Aug 13.
4
Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments.近似等效性：生成支持替代成本效益治疗方法的证据。
J Clin Oncol. 2021 Mar 20;39(9):950-955. doi: 10.1200/JCO.20.02768. Epub 2021 Feb 8.
5
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.纳武利尤单抗对比 1 年固定疗程治疗既往治疗的晚期非小细胞肺癌：CheckMate 153 研究
J Clin Oncol. 2020 Nov 20;38(33):3863-3873. doi: 10.1200/JCO.20.00131. Epub 2020 Sep 10.
6
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.抗 PD-1 抗体治疗在无疾病进展或治疗限制毒性的情况下停药：晚期黑色素瘤的临床结局。
Ann Oncol. 2019 Jul 1;30(7):1154-1161. doi: 10.1093/annonc/mdz110.
7
Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab.肿瘤生长抑制的转化药代动力学/药效学模型支持抗PD-1抗体帕博利珠单抗的剂量范围选择。
CPT Pharmacometrics Syst Pharmacol. 2017 Jan;6(1):11-20. doi: 10.1002/psp4.12130. Epub 2016 Nov 8.
8
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.帕博利珠单抗（MK-3475；抗 PD-1 单克隆抗体）治疗晚期实体瘤患者的 I 期研究。
Clin Cancer Res. 2015 Oct 1;21(19):4286-93. doi: 10.1158/1078-0432.CCR-14-2607. Epub 2015 May 14.